Commercial Metals Third-Quarter Results Miss Views as North American Steel Sales Fall
Melden Sie sich an, um Ihr Portfolio aufzurufen.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Coca-Cola (NYSE:KO) Posts Q2 Sales In Line With Estimates
Beverage company Coca-Cola (NYSE:KO) met Wall Street's revenue expectations in Q2 CY2025, with sales up 1.4% year on year to $12.54 billion. Its non-GAAP profit of $0.87 per share was 3.9% above analysts' consensus estimates. Is now the time to buy Coca-Cola? Find out in our full research report. Coca-Cola (KO) Q2 CY2025 Highlights: Revenue: $12.54 billion vs analyst estimates of $12.55 billion (1.4% year-on-year growth, in line) Adjusted EPS: $0.87 vs analyst estimates of $0.84 (3.9% beat) Roughly maintained full-year guidance for organic growth and adjusted EPS Operating Margin: 34.1%, up from 21.3% in the same quarter last year Free Cash Flow Margin: 26.9%, up from 25.6% in the same quarter last year Organic Revenue rose 5% year on year (15% in the same quarter last year) Sales Volumes fell 1% year on year (2% in the same quarter last year) Market Capitalization: $301.6 billion Company Overview A pioneer and behemoth in carbonated soft drinks, Coca-Cola (NYSE:KO) is a storied beverage company best known for its flagship soda. Revenue Growth Examining a company's long-term performance can provide clues about its quality. Any business can put up a good quarter or two, but many enduring ones grow for years. With $47.15 billion in revenue over the past 12 months, Coca-Cola is one of the most widely recognized consumer staples companies. Its influence over consumers gives it negotiating leverage with distributors, enabling it to pick and choose where it sells its products (a luxury many don't have). However, its scale is a double-edged sword because there are only a finite number of major retail partners, placing a ceiling on its growth. For Coca-Cola to boost its sales, it likely needs to adjust its prices, launch new offerings, or lean into foreign markets. As you can see below, Coca-Cola grew its sales at a tepid 4.5% compounded annual growth rate over the last three years, but to its credit, consumers bought more of its products. This quarter, Coca-Cola grew its revenue by 1.4% year on year, and its $12.54 billion of revenue was in line with Wall Street's estimates. Looking ahead, sell-side analysts expect revenue to grow 5.3% over the next 12 months, similar to its three-year rate. This projection is above the sector average and indicates its newer products will help support its historical top-line performance. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Volume Growth Revenue growth can be broken down into changes in price and volume (the number of units sold). While both are important, volume is the lifeblood of a successful staples business as there's a ceiling to what consumers will pay for everyday goods; they can always trade down to non-branded products if the branded versions are too expensive. To analyze whether Coca-Cola generated its growth from changes in price or volume, we can compare its volume growth to its organic revenue growth, which excludes non-fundamental impacts on company financials like mergers and currency fluctuations. Over the last two years, Coca-Cola's average quarterly volume growth was a healthy 1.1%. Even with this good performance, we can see that most of the company's gains have come from price increases by looking at its 10.4% average organic revenue growth. The ability to sell more products while raising prices indicates that Coca-Cola enjoys some degree of inelastic demand. In Coca-Cola's Q2 2025, sales volumes dropped 1% year on year. This result was a reversal from its historical levels. A one quarter hiccup shouldn't deter you from investing in a business, and we'll be monitoring the company to see how things progress. Key Takeaways from Coca-Cola's Q2 Results Revenue was in line while EPS beat partly due to better-than-expected gross margin. The company roughly maintained full-year guidance for organic growth and adjusted EPS, which is comforting. Overall, this was a quarter with few surprises. The stock remained flat at $69.93 immediately after reporting. Coca-Cola underperformed this quarter, but does that create an opportunity to invest right now? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28 minutes ago
- Yahoo
Dodge and Cox Increased its Holdings in UnitedHealth Group Incorporated (UNH) Amid Current Challenges
Dodge & Cox Fund, an investment management company, released its 'Dodge and Cox Stock Fund' second quarter 2025 investor letter. A copy of the letter can be downloaded here. The Stock Fund — Class I – returned 3.82% and Class X returned 3.85% in the second quarter vs the S&P 500 Index's 10.9% return and the Russell 1000 Value Index's 3.79% return. In the second quarter, geopolitical uncertainty and rapidly changing economic proposals led to increased volatility in the US markets. In addition, please check the fund's top five holdings to know its best picks in 2025. In its second quarter 2025 investor letter, Dodge and Cox Stock Fund highlighted stocks such as UnitedHealth Group Incorporated (NYSE:UNH). UnitedHealth Group Incorporated (NYSE:UNH) is a diversified healthcare company that operates through UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx segments. The one-month return of UnitedHealth Group Incorporated (NYSE:UNH) was -6.17%, and its shares lost 49.49% of their value over the last 52 weeks. On July 21, 2025, UnitedHealth Group Incorporated (NYSE:UNH) stock closed at $282.14 per share, with a market capitalization of $255.94 billion. Dodge and Cox Stock Fund stated the following regarding UnitedHealth Group Incorporated (NYSE:UNH) in its second quarter 2025 investor letter: "In the second quarter, we continued to add to holdings in the Health Care sector and trim select holdings in Financials, consistent with actions begun in early 2024. We increased the Fund's position in UnitedHealth Group Incorporated (NYSE:UNH), the largest U.S. health insurer, after the company's valuation reached an 11-year low due to disappointing earnings, continued regulatory concerns, and management changes.3 Its Medicare Advantage (MA) business has been especially weak, mirroring trends at the other largest MA participants (Humana and CVS, companies the Fund also owns). Despite the current challenges, we believe UnitedHealth has a strong position across its major markets and MA profitability is likely to recover. We are also optimistic that UnitedHealth's returning CEO Stephen Hemsley (who came out of retirement in May) can help improve operational efficiency and margins." A senior healthcare professional giving advice to a patient in a clinic. UnitedHealth Group Incorporated (NYSE:UNH) is in 18th position on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 139 hedge fund portfolios held UnitedHealth Group Incorporated (NYSE:UNH) at the end of the first quarter, which was 150 in the previous quarter. While we acknowledge the potential of UnitedHealth Group Incorporated (NYSE:UNH) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered UnitedHealth Group Incorporated (NYSE:UNH) and shared the list of most undervalued healthcare stocks to buy according to analysts. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
28 minutes ago
- Yahoo
Northrop hikes full-year outlook as strong Q2 print beats forecasts
-- Northrop Grumman (NYSE:NOC) shares jumped more than 3% in premarket trading Tuesday after the aerospace and defense technology company lifted its full-year outlook and reported second-quarter top and bottom line that beat market expectations. The company posted Q2 earnings per share (EPS) of $8.15, surpassing analyst expectations of $6.82. Revenue for the quarter reached $10.4 billion, also above the $10.07 billion consensus estimate. Northrop reported an operating margin of 13.8% and a segment operating margin of 11.8%. It returned more than $700 million to shareholders during the quarter through dividends and share buybacks. 'The Northrop Grumman team delivered a strong second quarter, with increased sales and outstanding operating performance,' said Kathy Warden, chair, CEO and president of Northrop. 'With confidence in our team and our ability to deliver for our customers, we are increasing our full-year guidance for segment operating income, EPS and free cash flow.' The company now expects EPS of $25.00 to $25.40, up from a prior range of $24.95 to $25.35, compared with the $25.20 consensus. Segment operating income outlook is raised to $4.275 billion to $4.375 billion, and free cash flow is forecast between $3.05 billion and $3.35 billion. Related articles Northrop hikes full-year outlook as strong Q2 print beats forecasts These Under-the-Radar Stocks Offer Better Risk-Reward Ratio Than Nvidia After soaring 149%, this stock is back in our AI's favor - & already +25% in July
